

**58th Meeting of the NCI Director's Consumer Liaison Group, September 21-23, 2011
Meeting Bibliography**

Abbruzzese

- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. [*Cell.* 2011;144\(5\):646-674.](#)
- Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. [*Science.* 2008;321\(5897\):1801-1806.](#)
- Aguirre AJ, Bardeesy N, Sinha M. Activated Kras and *Ink4a/Arf* deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. [*Genes Dev.* 2003;17\(24\):3112-3126.](#)
- Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. [*Clin Cancer Res.* 2000;6\(8\):2969-2972.](#)
- Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. [*Cancer Cell.* 2003;4\(6\):437-450.](#)
- Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. [*J Clin Oncol.* 1997;15\(6\):2403-2413.](#)
- Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. [*J Clin Oncol.* 2010;28\(22\):3605-3610.](#)
- Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. [*J Clin Oncol.* 2006;24\(16\):2505-2512.](#)
- Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. [*Cancer Discov.* 2011;1:44-53.](#)
- Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. [*Nat Med.* 2011;17\(3\):297-303.](#)
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. [*N Engl J Med.* 2010;363\(18\):1693-1703.](#)
- Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. [*N Engl J Med.* 2010;363\(9\):809-819.](#)
- Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. [*ASCO 2010 Annual Meeting. Abstract #3534.*](#)
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. [*N Engl J Med.* 2011;364\(26\):2507-2516.](#)

Giaccone

- Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer.* 2007;7(3):169-181.
- Wahbah, M Boroumand N, Castro C, et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. *Ann Diagn Pathol.* 2007;11(2):89-96.
- Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 2010;11(2):121-128.
- Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med.* 2010;362(25):2380-2388.
- Engelman JA, Zejnnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. *Cancer Res.* 2007;67(24):11924-11932.
- Kelly RJ, Carter C, Giaccone G. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. *J Clin Oncol.* 2010;28(28): e507-e510.
- Harada T, Lopez-Chavez A, Xi L, et al. Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. *Oncogene.* 2010;30(15):1744-1752.
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer. *Nature.* 2007;448(7153):561-566.
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med.* 2010;363(18):1693-1703.
- Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med.* 2010;363(18):1734-1739.
- Li Y, Ye X, Liu J, et al. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. *Neoplasia.* 2011;13(1):1-11.
- Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. *J Clin Oncol.* 2010;28(33):4953-4960.
- Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature.* 2008;455(7216):1069-1075.
- MacConaill LE, Garraway LA. Clinical implications of the cancer genome. *J Clin Oncol.* 2010;28(35):5219-5228.
- Janne PA, Reckamp K, Koczywas M, et al. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. *2009 ASCO Annual Meeting. Abstract 8063.*
- Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). *2010 ASCO Annual Meeting. Abstract 3.*

Khan

- Khan J, Wei JS, Ringnér M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. [*Nat Med.* 2001;7\(6\):673-679.](#)
- Chen QR, Vasant G, Oades K, et al. Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. [*J Mol Diagn.* 2007;9\(1\):80-88.](#)
- Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. [*Cancer Res.* 2004;64\(19\):6883-6891.](#)
- Taylor JG VI, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. [*J Clin Invest.* 2009;119\(11\):3395-3407.](#)
- Paulson V, Chandler G, Rakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. [*Genes Chromosomes Cancer.* 2011;50\(6\):397-408.](#)
- Overington JP, Al-Lizikani B, Hopkins AL. How many drug targets are there? [*Nat Rev Drug Discov.* 2006;5\(12\):993-996.](#)
- Harris T. Gene and drug matrix for personalized cancer therapy. [*Nat Rev Drug Discov.* 2010;9\(8\):660.](#)

Kummar

- DiMasi JA. New drug development in the United States from 1963 to 1999. [*Clin Pharmacol Ther.* 2001;69\(5\):286-296.](#)
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? [*Nat Rev Drug Discov.* 2004;3\(8\):711-715.](#)
- Goulart BH, Clark JW, Pien HH, et al. Trends in the use and role of biomarkers in phase I oncology trials. [*Clin Cancer Res.* 2007;13\(22 Pt 1\):6719-6726.](#)
- Kummar S, Doroshow JH, Tomaszewski JE, et al. Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. [*Eur J Cancer.* 2009;45\(5\):741-746.](#)
- Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. [*J Clin Oncol.* 2009;27\(16\):2705-2711.](#)
- Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. [*Cancer Res.* 2011; 71\(17\): 5626-5634.](#)
- U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). [*Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies.* January 2006.](#)

McShane

- McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. [*Clin Cancer Res.* 2009;15\(6\):1898-1905.](#)
- Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. [*J Clin Oncol.* 2005;23\(28\):7199-7206.](#)
- Freidlin B, Korn KL, Gray R, et al. Multi-arm clinical trials of new agents: some design considerations. [*Clin Cancer Res.* 2008;14\(14\):4368-4371.](#)
- Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. [*J Natl Cancer Inst.* 2010;102\(3\):152-160.](#)
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. [*N Engl J Med.* 2009;361\(10\):947-957.](#)

Conley

- Simon R, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. [*J Natl Cancer Inst.* 2009;101\(21\):1446-1452.](#)
- Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. [*J Natl Cancer Inst.* 1997;89\(2\):158-165.](#)
- Pajak TF, Clark GM, Sargent DJ, et al. Statistical issues in tumor marker studies. [*Arch Pathol Lab Med.* 2000;124\(7\):1011-1015.](#)
- Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. [*J Natl Cancer Inst.* 2007;99\(11\):838-846.](#)

Berry and Perlmutter

- Woodcock J, Griffin JD, Behrman RE. Development of novel combination therapies. [*N Engl J Med.* 2011;364\(11\):985-987.](#)
- Berry DA, Thor AD, Jewell SD, et al. Benefits of adding paclitaxel to adjuvant doxorubicin/cyclophosphamide depending on HER2 & ER status: analysis of tumor tissue microarrays and immunohistochemistry in CALGB 9344 (Intergroup 0148). [*2009 San Antonio Breast Cancer Symposium. Abstract 606.*](#)
- U.S. Department of Health and Human Services. Food and Drug Administration. Center for Devices and Radiological Health. [*Guidance for Industry and FDA Staff: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials.* February 2010.](#)
- U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). [*Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics.* February 2010.](#)
- Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. [*Cancer Discov.* 2011;1:44-53.](#)
- BIO/BioMedTracker. Clinical trial success rates study. [*BIO CEO & Investor Conference. February 15, 2011.*](#)

- U.S. Food and Drug Administration. Critical Path Initiative. <http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm>
- Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. *N Engl J Med.* 2009;360(20):2055-2065.
- Rubin EH, Anderson KM, Gause CK. The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development. *Cancer Discov.* 2011;1(1).
- I-SPY 2 trial: Neoadjuvant and personalized adaptive novel agents to treat breast cancer. [ClinicalTrials.gov](#).
- Winslow R. A new Rx for medicine. *The Wall Street Journal.* October 2, 2010.

Chen

- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature.* 2002;417(6892):949-954.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med.* 2011;364(26):2507-2516.
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer. *Nature.* 2007;448(7153):561-566.
- Hecht JR, Mitchell E, Chidac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol.* 2009;27(5):672-680.
- Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med.* 2009;360(6):563-572.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144(5):646-674.
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004;350(21):2129-2139.
- Paez JG, Janne PA, Lee JC. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science.* 2004;304(5676):1497-1500.
- Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. *Clin Cancer Res.* 2009;15(14):4649-4664.
- O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res.* 2006;66(3):1500-1508.
- Patnaik A, Ricart A, Cooper J, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. [2007 ASCO Annual Meeting. Abstract 3512.](#)

Wold

- Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A.* 2009;106(23):9414-9418.